 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
BIOMARIN PHARMACE, (BMRN) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of biopharmaceuticals and therapeutics for serious diseases and medical conditions. Its product portfolio comprises two approved products and various investigational product candidates. The company offers Aldurazyme for the treatment of mucopolysaccharidosis I, a progressive and debilitating life-threatening genetic disease that frequently results in death during childhood or early adulthood; and has rights to market and sell Orapred, a drug primarily used to treat asthma exacerbations in children, as well as rights to the Orapred intellectual property and two additional proprietary formulations of Orapred in development. BioMarin Pharmaceutical also develops various other product candidates for the treatment of genetic diseases comprising rhASB for the treatment of mucopolysaccharidosis VI; Phenoptin, a proprietary synthetic oral form of tetrahydrobiopterin for the treatment of moderate to mild forms of phenylketonuria (PKU); and Phenylase, a preclinical candidate for the treatment of the more severe form of PKU. In addition, the company develops preclinical stage multiple enzyme-based therapies that comprise Vibrilase, an investigational topical enzyme therapy for use in the debridement of serious burns; NeuroTrans, which would enable large molecules to be transported across the blood-brain barrier by means of traditional intravenous delivery; Immune Tolerance for immune response induced by protein-based therapies; and Phenylase, an injectable enzyme therapy for PKU. BioMarin Pharmaceutical has a joint venture, BioMarin/Genzyme LLC, with Genzyme Corporation for the development and commercialization of Aldurazyme, as well as a strategic business partnership with Daiichi Suntory Pharma Co., Ltd. for Phenoptin. The company is headquartered in Novato, California.
|
|
|
|
|
